INNOVACAP · NSE
Innova Captab Limited
₹1,179.8
+2.64% (+₹30.3)
Prev. close
₹1,149.5
Volume
32,076
Delivery %
61.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors, stockists, and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Manoj Kumar Lohariwala
Headquarters
Panchkula
Website
innovacaptab.comExchange
View on NSE ↗Key stats
Market cap
₹6,751.40 Cr
P/E ratio (TTM)
43.9
Dividend yield
0.35%
EPS (TTM)
₹26.90
Beta (1Y · daily vs NIFTY 50)
0.39
Shares float
1.59 Cr
EPS · quarter ended Jun 2026
₹7.71
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹925.40 Cr | ₹1,081.31 Cr | ₹1,234.42 Cr | ₹1,630.02 Cr | |
| EBITDA | — | — | ₹121.81 Cr | ₹166.94 Cr | ₹198.04 Cr | ₹250.34 Cr |
| ₹34.00 Cr | ₹64.00 Cr | ₹67.95 Cr | ₹94.35 Cr | ₹128.26 Cr | ₹140.92 Cr | |
| Diluted EPS | — | — | ₹11.87 | ₹18.66 | ₹22.41 | ₹24.63 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹370.00 Cr | ₹575.00 Cr | ₹704.00 Cr | ₹1,316.00 Cr | ₹1,568.00 Cr | ₹1,836.00 Cr | |
| — | — | ₹236.97 Cr | ₹245.10 Cr | ₹338.12 Cr | ₹343.69 Cr | |
| Stockholders' equity | ₹145.00 Cr | ₹209.00 Cr | ₹277.00 Cr | ₹831.00 Cr | ₹959.00 Cr | ₹1,091.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹42.00 Cr | ₹59.00 Cr | ₹67.00 Cr | ₹146.00 Cr | ₹64.00 Cr | ₹117.00 Cr | |
| Investing cash flow | — | — | ₹-90.84 Cr | ₹-498.97 Cr | ₹-151.59 Cr | ₹-107.12 Cr |
| ₹-19.00 Cr | ₹125.00 Cr | ₹27.00 Cr | ₹361.00 Cr | ₹92.00 Cr | ₹-22.00 Cr | |
| Capital expenditure | — | — | ₹-78.99 Cr | ₹-287.35 Cr | ₹-172.50 Cr | ₹-68.35 Cr |
| End cash position | — | — | ₹3.53 Cr | ₹11.73 Cr | ₹15.52 Cr | ₹3.20 Cr |
Change in working capital, Investing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 23–Jun 26(12Q) |
|---|---|
| Promoter | 50.90% |
| Public | 49.10% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Innova Captab Limited | ₹6,598.03 Cr | ₹1,147.2 | 42.8 | 6.05 | 12.9% | 0.32 | +29.9% | +33.7% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
4 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Innova Captab: FY26 Annual Report & AGM Notice Available
Innova Captab Limited announced the availability of its Integrated Annual Report for FY2025-26 and the Notice for its 22nd Annual General Meeting. The AGM is scheduled for September 30, 2026, and will be held via video conference. The company is sending physical letters with web links to shareholders with unregistered email addresses.
Innova Captab Board Approves INR 50 Crore Land Acquisition Proposal
Innova Captab Limited's Board of Directors has approved a proposal to acquire land for approximately INR 50 crore. This strategic investment aims to support the pharmaceutical manufacturing company's future operational expansion. The company's shares were trading higher following the announcement.